| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 225 | 2023 | 1660 | 13.350 |
Why?
|
| Smoking | 190 | 2017 | 1047 | 9.100 |
Why?
|
| Polymorphism, Genetic | 83 | 2014 | 816 | 4.160 |
Why?
|
| Polymorphism, Single Nucleotide | 93 | 2023 | 2635 | 4.050 |
Why?
|
| DNA Repair | 65 | 2012 | 585 | 3.970 |
Why?
|
| Carcinoma, Squamous Cell | 76 | 2016 | 666 | 3.870 |
Why?
|
| Mexican Americans | 37 | 2019 | 202 | 3.780 |
Why?
|
| Case-Control Studies | 226 | 2019 | 3294 | 3.690 |
Why?
|
| Head and Neck Neoplasms | 68 | 2015 | 503 | 3.620 |
Why?
|
| Genetic Predisposition to Disease | 143 | 2023 | 3156 | 3.610 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 42 | 2016 | 350 | 3.470 |
Why?
|
| Mutagens | 38 | 2007 | 84 | 3.200 |
Why?
|
| Lymphocytes | 58 | 2011 | 410 | 2.540 |
Why?
|
| Risk Factors | 216 | 2019 | 10270 | 2.220 |
Why?
|
| Neoplasms | 45 | 2015 | 2783 | 2.120 |
Why?
|
| Receptors, Nicotinic | 19 | 2016 | 154 | 2.060 |
Why?
|
| Middle Aged | 313 | 2019 | 26888 | 2.060 |
Why?
|
| Bleomycin | 39 | 2008 | 153 | 2.030 |
Why?
|
| Chromosome Aberrations | 37 | 2015 | 612 | 1.980 |
Why?
|
| Genetic Variation | 33 | 2019 | 1499 | 1.920 |
Why?
|
| Genome-Wide Association Study | 42 | 2023 | 1686 | 1.890 |
Why?
|
| Chromosomes, Human, Pair 15 | 14 | 2016 | 160 | 1.870 |
Why?
|
| Aged | 218 | 2018 | 19831 | 1.690 |
Why?
|
| Male | 367 | 2022 | 61388 | 1.660 |
Why?
|
| Adenocarcinoma | 31 | 2017 | 1023 | 1.610 |
Why?
|
| Genotype | 99 | 2017 | 2561 | 1.590 |
Why?
|
| Female | 362 | 2021 | 66672 | 1.580 |
Why?
|
| DNA Damage | 30 | 2012 | 513 | 1.500 |
Why?
|
| Humans | 487 | 2023 | 124936 | 1.480 |
Why?
|
| Adolescent Behavior | 10 | 2019 | 168 | 1.470 |
Why?
|
| Carcinogens | 25 | 2010 | 152 | 1.410 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 26 | 2007 | 34 | 1.380 |
Why?
|
| Odds Ratio | 70 | 2016 | 1254 | 1.380 |
Why?
|
| Biomarkers, Tumor | 24 | 2016 | 1492 | 1.340 |
Why?
|
| Molecular Epidemiology | 15 | 2012 | 155 | 1.220 |
Why?
|
| DNA-Binding Proteins | 32 | 2022 | 2049 | 1.150 |
Why?
|
| Neoplasms, Second Primary | 15 | 2012 | 151 | 1.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 13 | 2019 | 120 | 1.110 |
Why?
|
| Urinary Bladder Neoplasms | 20 | 2007 | 557 | 1.110 |
Why?
|
| Insulin-Like Growth Factor I | 11 | 2006 | 341 | 1.080 |
Why?
|
| Diet | 22 | 2013 | 1140 | 1.080 |
Why?
|
| Mouth Neoplasms | 17 | 2008 | 84 | 1.050 |
Why?
|
| Risk | 48 | 2016 | 754 | 1.000 |
Why?
|
| Carcinoma | 9 | 2010 | 287 | 0.980 |
Why?
|
| Epidemiology | 2 | 2015 | 9 | 0.950 |
Why?
|
| Mutagenicity Tests | 15 | 2007 | 36 | 0.940 |
Why?
|
| Tobacco Use Disorder | 10 | 2015 | 89 | 0.920 |
Why?
|
| Prostatic Neoplasms | 20 | 2015 | 1546 | 0.890 |
Why?
|
| Inflammation | 12 | 2015 | 1442 | 0.880 |
Why?
|
| Professional Competence | 2 | 2015 | 95 | 0.880 |
Why?
|
| Adult | 151 | 2018 | 29587 | 0.880 |
Why?
|
| Attitude to Health | 4 | 2014 | 256 | 0.870 |
Why?
|
| Logistic Models | 38 | 2014 | 1808 | 0.870 |
Why?
|
| Tobacco Smoke Pollution | 6 | 2012 | 76 | 0.870 |
Why?
|
| Smoking Cessation | 16 | 2016 | 198 | 0.860 |
Why?
|
| Small Cell Lung Carcinoma | 6 | 2016 | 33 | 0.820 |
Why?
|
| Texas | 54 | 2014 | 3584 | 0.810 |
Why?
|
| Nerve Tissue Proteins | 14 | 2016 | 1113 | 0.800 |
Why?
|
| Alleles | 27 | 2016 | 1615 | 0.800 |
Why?
|
| Telomerase | 9 | 2019 | 160 | 0.740 |
Why?
|
| Alcohol Drinking | 26 | 2019 | 343 | 0.730 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 9 | 2006 | 54 | 0.720 |
Why?
|
| Genes, p53 | 8 | 2006 | 212 | 0.710 |
Why?
|
| Models, Statistical | 7 | 2013 | 471 | 0.700 |
Why?
|
| Aged, 80 and over | 56 | 2018 | 6583 | 0.690 |
Why?
|
| Rhinitis, Allergic, Seasonal | 5 | 2013 | 24 | 0.650 |
Why?
|
| Motor Activity | 3 | 2012 | 521 | 0.650 |
Why?
|
| Risk Assessment | 27 | 2022 | 3449 | 0.640 |
Why?
|
| Pharyngeal Neoplasms | 10 | 2008 | 26 | 0.640 |
Why?
|
| Hormone Replacement Therapy | 4 | 2012 | 196 | 0.630 |
Why?
|
| Linkage Disequilibrium | 16 | 2013 | 309 | 0.610 |
Why?
|
| DNA Adducts | 11 | 2010 | 77 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 3 | 5 | 2008 | 95 | 0.600 |
Why?
|
| DNA, Neoplasm | 17 | 2011 | 303 | 0.600 |
Why?
|
| Family Health | 10 | 2017 | 259 | 0.600 |
Why?
|
| Multivariate Analysis | 22 | 2015 | 1437 | 0.600 |
Why?
|
| BRCA2 Protein | 2 | 2015 | 45 | 0.590 |
Why?
|
| Glutathione Transferase | 10 | 2008 | 155 | 0.590 |
Why?
|
| Sex Factors | 27 | 2014 | 1286 | 0.580 |
Why?
|
| Laryngeal Neoplasms | 9 | 2007 | 83 | 0.580 |
Why?
|
| Acculturation | 6 | 2014 | 68 | 0.580 |
Why?
|
| Cocarcinogenesis | 6 | 2011 | 23 | 0.580 |
Why?
|
| Cell Cycle | 5 | 2011 | 619 | 0.560 |
Why?
|
| Pain | 5 | 2013 | 451 | 0.560 |
Why?
|
| Somatomedins | 3 | 2002 | 37 | 0.540 |
Why?
|
| Gene Frequency | 27 | 2015 | 724 | 0.540 |
Why?
|
| Prognosis | 27 | 2016 | 4624 | 0.530 |
Why?
|
| Disease Susceptibility | 26 | 2005 | 298 | 0.520 |
Why?
|
| Isotretinoin | 6 | 2012 | 26 | 0.520 |
Why?
|
| Neoplasm Staging | 19 | 2016 | 1273 | 0.510 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2006 | 32 | 0.500 |
Why?
|
| Promoter Regions, Genetic | 10 | 2011 | 1331 | 0.490 |
Why?
|
| Polymerase Chain Reaction | 33 | 2016 | 1583 | 0.490 |
Why?
|
| Cohort Studies | 20 | 2016 | 4806 | 0.480 |
Why?
|
| Genetic Markers | 11 | 2013 | 603 | 0.480 |
Why?
|
| Peroxidase | 6 | 2007 | 69 | 0.470 |
Why?
|
| Germ-Line Mutation | 2 | 2016 | 333 | 0.460 |
Why?
|
| Confidence Intervals | 19 | 2014 | 285 | 0.460 |
Why?
|
| Social Perception | 3 | 2009 | 56 | 0.450 |
Why?
|
| Health Behavior | 5 | 2011 | 385 | 0.450 |
Why?
|
| Folic Acid | 6 | 2013 | 294 | 0.450 |
Why?
|
| Age Factors | 31 | 2014 | 2817 | 0.440 |
Why?
|
| Cotinine | 3 | 2013 | 23 | 0.430 |
Why?
|
| Dust | 3 | 2006 | 19 | 0.430 |
Why?
|
| Neoplasms, Multiple Primary | 7 | 1994 | 71 | 0.420 |
Why?
|
| Haplotypes | 14 | 2014 | 522 | 0.410 |
Why?
|
| Salivary Gland Neoplasms | 6 | 1990 | 55 | 0.410 |
Why?
|
| DNA Helicases | 8 | 2005 | 231 | 0.410 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 7 | 2018 | 601 | 0.410 |
Why?
|
| Sensation | 1 | 2012 | 57 | 0.400 |
Why?
|
| Membrane Proteins | 6 | 2019 | 1527 | 0.400 |
Why?
|
| In Situ Hybridization, Fluorescence | 12 | 2010 | 763 | 0.400 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 6 | 0.400 |
Why?
|
| Proteins | 9 | 2015 | 1036 | 0.390 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 53 | 0.390 |
Why?
|
| United States | 41 | 2015 | 10899 | 0.390 |
Why?
|
| Genome, Human | 10 | 2015 | 1274 | 0.380 |
Why?
|
| Precancerous Conditions | 8 | 2008 | 282 | 0.380 |
Why?
|
| Exome | 2 | 2016 | 1033 | 0.380 |
Why?
|
| Health Promotion | 2 | 2014 | 389 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 173 | 0.370 |
Why?
|
| Adolescent | 42 | 2019 | 19303 | 0.370 |
Why?
|
| Reproductive History | 1 | 2011 | 10 | 0.370 |
Why?
|
| Wood | 2 | 2005 | 9 | 0.370 |
Why?
|
| Proportional Hazards Models | 15 | 2014 | 1356 | 0.370 |
Why?
|
| Digoxin | 1 | 2011 | 43 | 0.360 |
Why?
|
| Phenotype | 16 | 2016 | 4259 | 0.350 |
Why?
|
| Cytochrome P-450 CYP2E1 | 3 | 2005 | 8 | 0.350 |
Why?
|
| Predictive Value of Tests | 15 | 2011 | 2164 | 0.340 |
Why?
|
| Prospective Studies | 20 | 2014 | 6145 | 0.340 |
Why?
|
| Regression Analysis | 15 | 2011 | 779 | 0.340 |
Why?
|
| Occupational Exposure | 7 | 2012 | 127 | 0.340 |
Why?
|
| Nuclear Proteins | 9 | 2011 | 1266 | 0.330 |
Why?
|
| ROC Curve | 7 | 2014 | 569 | 0.330 |
Why?
|
| Environmental Exposure | 8 | 2012 | 220 | 0.330 |
Why?
|
| Insulin-Like Growth Factor II | 4 | 2003 | 41 | 0.330 |
Why?
|
| Antibiotics, Antineoplastic | 9 | 2006 | 127 | 0.330 |
Why?
|
| Life Style | 4 | 2011 | 414 | 0.320 |
Why?
|
| Family | 3 | 2012 | 565 | 0.320 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2000 | 44 | 0.320 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 7 | 2013 | 70 | 0.320 |
Why?
|
| Chromatids | 9 | 2006 | 43 | 0.320 |
Why?
|
| Breast Neoplasms | 9 | 2015 | 2511 | 0.310 |
Why?
|
| Social Environment | 2 | 2011 | 120 | 0.310 |
Why?
|
| Incidence | 21 | 2014 | 3134 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2008 | 86 | 0.310 |
Why?
|
| Cytokines | 3 | 2013 | 1286 | 0.310 |
Why?
|
| Transcription Factors | 10 | 2007 | 2594 | 0.300 |
Why?
|
| Telomere | 3 | 2006 | 213 | 0.300 |
Why?
|
| Mosaicism | 3 | 2016 | 239 | 0.300 |
Why?
|
| Smoking Prevention | 5 | 2014 | 37 | 0.300 |
Why?
|
| Exons | 14 | 2008 | 797 | 0.300 |
Why?
|
| Age of Onset | 9 | 2016 | 591 | 0.300 |
Why?
|
| Epidemiologic Methods | 9 | 2014 | 110 | 0.300 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2012 | 469 | 0.300 |
Why?
|
| Cytokinesis | 4 | 2014 | 28 | 0.300 |
Why?
|
| Ultraviolet Rays | 8 | 2005 | 203 | 0.300 |
Why?
|
| Area Under Curve | 5 | 2014 | 316 | 0.300 |
Why?
|
| Cisplatin | 2 | 2010 | 249 | 0.300 |
Why?
|
| Surveys and Questionnaires | 26 | 2014 | 3721 | 0.290 |
Why?
|
| Cell Cycle Proteins | 7 | 2010 | 656 | 0.290 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2008 | 34 | 0.290 |
Why?
|
| Body Mass Index | 9 | 2013 | 1562 | 0.290 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2004 | 135 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2011 | 723 | 0.290 |
Why?
|
| Respiratory Tract Neoplasms | 4 | 1998 | 14 | 0.290 |
Why?
|
| Gene Dosage | 2 | 2008 | 440 | 0.280 |
Why?
|
| Nitrosamines | 5 | 2013 | 19 | 0.280 |
Why?
|
| Germ Cells | 1 | 2008 | 195 | 0.280 |
Why?
|
| DNA Breaks | 1 | 2007 | 26 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2006 | 106 | 0.280 |
Why?
|
| Alkylating Agents | 1 | 2007 | 11 | 0.280 |
Why?
|
| Pilot Projects | 21 | 2013 | 1396 | 0.270 |
Why?
|
| Anticarcinogenic Agents | 6 | 1999 | 56 | 0.270 |
Why?
|
| Plants, Toxic | 6 | 1999 | 11 | 0.270 |
Why?
|
| Analysis of Variance | 8 | 2014 | 1019 | 0.270 |
Why?
|
| Phytoestrogens | 3 | 2005 | 16 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1252 | 0.270 |
Why?
|
| Asthma | 4 | 2008 | 754 | 0.260 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 42 | 0.260 |
Why?
|
| Radiation Pneumonitis | 2 | 2010 | 13 | 0.260 |
Why?
|
| Chi-Square Distribution | 10 | 2014 | 589 | 0.260 |
Why?
|
| Follow-Up Studies | 12 | 2016 | 5159 | 0.260 |
Why?
|
| Skin Neoplasms | 11 | 2005 | 862 | 0.260 |
Why?
|
| Genes, Tumor Suppressor | 8 | 2008 | 204 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2012 | 141 | 0.250 |
Why?
|
| Ferredoxin-NADP Reductase | 4 | 2013 | 10 | 0.250 |
Why?
|
| DNA Primers | 15 | 2015 | 657 | 0.250 |
Why?
|
| Gamma Rays | 10 | 2007 | 50 | 0.240 |
Why?
|
| Genetic Association Studies | 9 | 2018 | 778 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2012 | 1112 | 0.240 |
Why?
|
| Imitative Behavior | 2 | 2019 | 5 | 0.240 |
Why?
|
| Amifostine | 1 | 2005 | 14 | 0.240 |
Why?
|
| Motion Pictures | 2 | 2019 | 8 | 0.240 |
Why?
|
| Chromosomes, Human | 5 | 2014 | 130 | 0.240 |
Why?
|
| Air Pollutants, Occupational | 1 | 2005 | 18 | 0.240 |
Why?
|
| Radiation-Protective Agents | 1 | 2005 | 18 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2008 | 1698 | 0.240 |
Why?
|
| Pulmonary Emphysema | 2 | 2010 | 94 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2014 | 1050 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2005 | 80 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2010 | 824 | 0.230 |
Why?
|
| Gene-Environment Interaction | 3 | 2016 | 121 | 0.230 |
Why?
|
| Epoxide Hydrolases | 2 | 2002 | 37 | 0.230 |
Why?
|
| Genetics, Population | 6 | 2014 | 188 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 1999 | 49 | 0.230 |
Why?
|
| Chemoprevention | 4 | 2006 | 58 | 0.230 |
Why?
|
| Biomedical Research | 4 | 2015 | 519 | 0.220 |
Why?
|
| Cells, Cultured | 13 | 2007 | 3054 | 0.220 |
Why?
|
| Neoplasm Proteins | 5 | 2014 | 670 | 0.220 |
Why?
|
| Survival Analysis | 9 | 2011 | 1503 | 0.220 |
Why?
|
| Antioxidants | 5 | 2008 | 369 | 0.220 |
Why?
|
| Peer Group | 5 | 2019 | 118 | 0.220 |
Why?
|
| Carcinogens, Environmental | 2 | 2015 | 16 | 0.220 |
Why?
|
| Epidemiologic Studies | 5 | 2013 | 43 | 0.220 |
Why?
|
| Base Sequence | 16 | 2015 | 3103 | 0.220 |
Why?
|
| Survival Rate | 9 | 2013 | 2056 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 691 | 0.210 |
Why?
|
| Mass Screening | 6 | 2022 | 784 | 0.210 |
Why?
|
| Folic Acid Deficiency | 1 | 2003 | 53 | 0.210 |
Why?
|
| Reference Values | 11 | 2012 | 715 | 0.210 |
Why?
|
| Age Distribution | 7 | 2007 | 417 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2014 | 1892 | 0.210 |
Why?
|
| Chromosome Breakage | 8 | 2006 | 167 | 0.210 |
Why?
|
| Tobacco, Smokeless | 4 | 2015 | 13 | 0.210 |
Why?
|
| Body Height | 2 | 2021 | 215 | 0.210 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 4 | 2005 | 26 | 0.210 |
Why?
|
| Carcinoma, Small Cell | 6 | 2010 | 51 | 0.200 |
Why?
|
| Prevalence | 11 | 2015 | 2451 | 0.200 |
Why?
|
| Polymorphism, Restriction Fragment Length | 11 | 2007 | 144 | 0.200 |
Why?
|
| Erythroplasia | 1 | 2002 | 2 | 0.200 |
Why?
|
| Leukoplakia, Oral | 1 | 2002 | 4 | 0.200 |
Why?
|
| Sensitivity and Specificity | 11 | 2010 | 2052 | 0.200 |
Why?
|
| Ascorbic Acid | 4 | 2001 | 78 | 0.200 |
Why?
|
| Gene Deletion | 4 | 1998 | 789 | 0.200 |
Why?
|
| DNA Glycosylases | 3 | 2010 | 32 | 0.200 |
Why?
|
| Quantitative Trait Loci | 3 | 2022 | 288 | 0.190 |
Why?
|
| Socioeconomic Factors | 10 | 2015 | 868 | 0.190 |
Why?
|
| Micronucleus Tests | 4 | 2012 | 7 | 0.190 |
Why?
|
| Fatigue | 2 | 2013 | 191 | 0.190 |
Why?
|
| Chromosomes | 4 | 2002 | 199 | 0.190 |
Why?
|
| Aging | 4 | 2016 | 1183 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2012 | 1140 | 0.190 |
Why?
|
| Pseudogenes | 2 | 1999 | 53 | 0.180 |
Why?
|
| Comet Assay | 5 | 2010 | 11 | 0.180 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 1999 | 61 | 0.180 |
Why?
|
| Digestive System Neoplasms | 2 | 1998 | 14 | 0.180 |
Why?
|
| Bayes Theorem | 5 | 2015 | 285 | 0.180 |
Why?
|
| Parents | 2 | 2007 | 1023 | 0.180 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 3 | 2005 | 21 | 0.180 |
Why?
|
| Radiation Injuries | 3 | 2010 | 142 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 9 | 2011 | 1062 | 0.180 |
Why?
|
| Cross-Sectional Studies | 8 | 2016 | 3416 | 0.180 |
Why?
|
| Chromosomes, Human, X | 2 | 2016 | 157 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2001 | 618 | 0.180 |
Why?
|
| Isothiocyanates | 1 | 2000 | 13 | 0.180 |
Why?
|
| Software | 3 | 2012 | 683 | 0.180 |
Why?
|
| Educational Status | 3 | 2014 | 276 | 0.180 |
Why?
|
| False Positive Reactions | 3 | 2012 | 144 | 0.170 |
Why?
|
| Europe | 6 | 2021 | 353 | 0.170 |
Why?
|
| Leptin | 2 | 2001 | 214 | 0.170 |
Why?
|
| DNA Methylation | 6 | 2016 | 1009 | 0.170 |
Why?
|
| Glypicans | 2 | 2010 | 35 | 0.170 |
Why?
|
| Research Design | 4 | 2008 | 694 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2A6 | 3 | 2014 | 13 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 2 | 1998 | 275 | 0.170 |
Why?
|
| Genetic Loci | 4 | 2014 | 339 | 0.170 |
Why?
|
| Dietary Fats | 2 | 1998 | 294 | 0.170 |
Why?
|
| Interviews as Topic | 7 | 2013 | 371 | 0.170 |
Why?
|
| Genomic Instability | 3 | 2012 | 229 | 0.160 |
Why?
|
| Body Composition | 1 | 2002 | 521 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2013 | 920 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 1997 | 33 | 0.160 |
Why?
|
| Carcinoma, Large Cell | 3 | 2016 | 9 | 0.160 |
Why?
|
| Sister Chromatid Exchange | 5 | 2007 | 18 | 0.160 |
Why?
|
| Obesity | 5 | 2013 | 2245 | 0.160 |
Why?
|
| Time Factors | 12 | 2015 | 6326 | 0.160 |
Why?
|
| Glycine Hydroxymethyltransferase | 3 | 2011 | 6 | 0.150 |
Why?
|
| Placebos | 4 | 2011 | 241 | 0.150 |
Why?
|
| Lung Diseases | 3 | 2013 | 384 | 0.150 |
Why?
|
| 4-Nitroquinoline-1-oxide | 3 | 1999 | 8 | 0.150 |
Why?
|
| Pharmacogenetics | 3 | 2010 | 184 | 0.150 |
Why?
|
| Mutagenesis | 2 | 1997 | 345 | 0.150 |
Why?
|
| Database Management Systems | 2 | 1988 | 31 | 0.150 |
Why?
|
| Signal Transduction | 5 | 2015 | 4537 | 0.150 |
Why?
|
| Asbestos | 2 | 2012 | 14 | 0.150 |
Why?
|
| In Vitro Techniques | 5 | 2007 | 980 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 362 | 0.150 |
Why?
|
| Antiporters | 1 | 1998 | 32 | 0.150 |
Why?
|
| Liver Neoplasms | 4 | 2013 | 1291 | 0.150 |
Why?
|
| Trace Elements | 2 | 2008 | 27 | 0.140 |
Why?
|
| Mexico | 5 | 2008 | 181 | 0.140 |
Why?
|
| Probability | 5 | 2019 | 321 | 0.140 |
Why?
|
| Health Maintenance Organizations | 1 | 1997 | 22 | 0.140 |
Why?
|
| Treatment Outcome | 12 | 2014 | 12374 | 0.140 |
Why?
|
| Databases, Factual | 4 | 2014 | 1179 | 0.140 |
Why?
|
| Cyclin D1 | 4 | 2008 | 112 | 0.140 |
Why?
|
| Trinucleotide Repeats | 2 | 2016 | 109 | 0.140 |
Why?
|
| Child | 19 | 2015 | 24318 | 0.140 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 576 | 0.140 |
Why?
|
| Minority Groups | 4 | 2004 | 248 | 0.140 |
Why?
|
| Multigene Family | 3 | 2013 | 299 | 0.140 |
Why?
|
| Sex Distribution | 4 | 2012 | 306 | 0.140 |
Why?
|
| Chromosome Mapping | 7 | 2017 | 1080 | 0.140 |
Why?
|
| Nicotine | 5 | 2012 | 143 | 0.140 |
Why?
|
| Fathers | 2 | 1989 | 68 | 0.140 |
Why?
|
| Isoflavones | 3 | 2005 | 45 | 0.140 |
Why?
|
| Codon | 7 | 2006 | 98 | 0.140 |
Why?
|
| Public Health | 3 | 2015 | 266 | 0.130 |
Why?
|
| Seasons | 2 | 1996 | 312 | 0.130 |
Why?
|
| Disease-Free Survival | 7 | 2012 | 898 | 0.130 |
Why?
|
| Chromosomal Instability | 2 | 2008 | 57 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 1997 | 61 | 0.130 |
Why?
|
| Melanoma | 7 | 2005 | 944 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1998 | 184 | 0.130 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 62 | 0.130 |
Why?
|
| Huntingtin Protein | 1 | 2016 | 63 | 0.130 |
Why?
|
| Exercise | 2 | 2012 | 813 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 2 | 2014 | 191 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2012 | 1696 | 0.130 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2014 | 36 | 0.130 |
Why?
|
| Parent-Child Relations | 2 | 2015 | 247 | 0.120 |
Why?
|
| 5' Untranslated Regions | 2 | 2006 | 58 | 0.120 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 441 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2003 | 237 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2012 | 335 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 848 | 0.120 |
Why?
|
| Young Adult | 6 | 2018 | 9035 | 0.120 |
Why?
|
| Family Conflict | 1 | 2015 | 18 | 0.120 |
Why?
|
| fas Receptor | 2 | 2006 | 41 | 0.120 |
Why?
|
| Proline | 1 | 1995 | 78 | 0.120 |
Why?
|
| International Agencies | 1 | 2015 | 29 | 0.120 |
Why?
|
| Huntington Disease | 1 | 2016 | 143 | 0.120 |
Why?
|
| Loss of Heterozygosity | 4 | 2007 | 124 | 0.120 |
Why?
|
| Apoptosis | 5 | 2011 | 1803 | 0.120 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 2886 | 0.120 |
Why?
|
| Thymidylate Synthase | 2 | 2004 | 22 | 0.120 |
Why?
|
| Publications | 1 | 2015 | 33 | 0.120 |
Why?
|
| Social Class | 3 | 2008 | 190 | 0.120 |
Why?
|
| Algorithms | 6 | 2012 | 1628 | 0.120 |
Why?
|
| Tumor Protein p73 | 4 | 2011 | 22 | 0.120 |
Why?
|
| Ethanol | 3 | 1996 | 163 | 0.120 |
Why?
|
| Tobacco Products | 2 | 2012 | 61 | 0.110 |
Why?
|
| Family Practice | 1 | 1995 | 91 | 0.110 |
Why?
|
| Tobacco Industry | 1 | 2014 | 8 | 0.110 |
Why?
|
| HLA-D Antigens | 1 | 2014 | 14 | 0.110 |
Why?
|
| Carrier Proteins | 3 | 2001 | 1024 | 0.110 |
Why?
|
| Depression | 2 | 2013 | 1236 | 0.110 |
Why?
|
| Residence Characteristics | 4 | 2012 | 278 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 19 | 0.110 |
Why?
|
| Risk-Taking | 2 | 2014 | 96 | 0.110 |
Why?
|
| Mass Media | 1 | 2014 | 28 | 0.110 |
Why?
|
| Interleukin-8 | 2 | 2012 | 209 | 0.110 |
Why?
|
| Homozygote | 9 | 2010 | 547 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2002 | 57 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2008 | 138 | 0.110 |
Why?
|
| Carotenoids | 2 | 2005 | 75 | 0.110 |
Why?
|
| Mutation | 7 | 2018 | 5847 | 0.110 |
Why?
|
| beta Carotene | 4 | 2005 | 41 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 241 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2014 | 154 | 0.110 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 6 | 2005 | 21 | 0.110 |
Why?
|
| Pain Measurement | 3 | 2009 | 347 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2005 | 25 | 0.110 |
Why?
|
| Endonucleases | 3 | 2002 | 54 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 130 | 0.110 |
Why?
|
| Leukemia | 3 | 1994 | 371 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 104 | 0.110 |
Why?
|
| Iron, Dietary | 1 | 2013 | 16 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2013 | 14 | 0.110 |
Why?
|
| Receptors, Cytokine | 1 | 2013 | 68 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2014 | 194 | 0.110 |
Why?
|
| Meat | 1 | 2013 | 48 | 0.100 |
Why?
|
| Cell Line | 8 | 2004 | 2757 | 0.100 |
Why?
|
| Drug-Seeking Behavior | 1 | 2012 | 6 | 0.100 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2012 | 12 | 0.100 |
Why?
|
| Body Image | 1 | 2013 | 38 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2013 | 214 | 0.100 |
Why?
|
| Biological Evolution | 2 | 2012 | 225 | 0.100 |
Why?
|
| Plasmids | 2 | 2007 | 512 | 0.100 |
Why?
|
| Thyroid Neoplasms | 2 | 2001 | 190 | 0.100 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 28 | 0.100 |
Why?
|
| Lipase | 1 | 2013 | 93 | 0.100 |
Why?
|
| Heme | 1 | 2013 | 52 | 0.100 |
Why?
|
| Nervous System Neoplasms | 2 | 1989 | 11 | 0.100 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2012 | 33 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 243 | 0.100 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2012 | 55 | 0.100 |
Why?
|
| Phytosterols | 2 | 2005 | 28 | 0.100 |
Why?
|
| Inhalation Exposure | 1 | 2012 | 36 | 0.100 |
Why?
|
| Tretinoin | 3 | 2005 | 118 | 0.100 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 351 | 0.100 |
Why?
|
| Dietary Supplements | 2 | 2008 | 473 | 0.100 |
Why?
|
| Selenium | 3 | 2007 | 22 | 0.100 |
Why?
|
| Disease Progression | 9 | 2011 | 2058 | 0.100 |
Why?
|
| Databases, Genetic | 2 | 2012 | 473 | 0.100 |
Why?
|
| DNA | 7 | 2006 | 1608 | 0.100 |
Why?
|
| Testicular Neoplasms | 4 | 1987 | 130 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 359 | 0.100 |
Why?
|
| Research Report | 1 | 2012 | 75 | 0.100 |
Why?
|
| Rad52 DNA Repair and Recombination Protein | 1 | 2011 | 6 | 0.100 |
Why?
|
| Progestins | 1 | 2012 | 48 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 488 | 0.100 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 678 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 434 | 0.090 |
Why?
|
| Statistics as Topic | 4 | 2012 | 256 | 0.090 |
Why?
|
| Transcription Factor AP-2 | 1 | 2011 | 22 | 0.090 |
Why?
|
| Airway Remodeling | 1 | 2011 | 21 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 4 | 2006 | 233 | 0.090 |
Why?
|
| Analgesics | 2 | 2009 | 127 | 0.090 |
Why?
|
| Phytohemagglutinins | 3 | 2007 | 13 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2013 | 173 | 0.090 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 2 | 2001 | 26 | 0.090 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 33 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2012 | 174 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 92 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 418 | 0.090 |
Why?
|
| Activin Receptors, Type I | 1 | 2011 | 34 | 0.090 |
Why?
|
| Matched-Pair Analysis | 3 | 2010 | 27 | 0.090 |
Why?
|
| CD30 Ligand | 1 | 2011 | 2 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2011 | 44 | 0.090 |
Why?
|
| Menarche | 1 | 2011 | 35 | 0.090 |
Why?
|
| Registries | 5 | 2003 | 1430 | 0.090 |
Why?
|
| Uterine Cervical Diseases | 1 | 1991 | 6 | 0.090 |
Why?
|
| Eating | 1 | 2013 | 367 | 0.090 |
Why?
|
| Feeding Behavior | 3 | 2013 | 701 | 0.090 |
Why?
|
| Models, Theoretical | 2 | 2012 | 362 | 0.090 |
Why?
|
| Health Surveys | 2 | 2009 | 242 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 98 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2010 | 29 | 0.090 |
Why?
|
| Genotyping Techniques | 3 | 2019 | 103 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2010 | 37 | 0.090 |
Why?
|
| Anxiety | 2 | 2015 | 959 | 0.090 |
Why?
|
| Statistics, Nonparametric | 4 | 2008 | 435 | 0.090 |
Why?
|
| Likelihood Functions | 2 | 2013 | 114 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2013 | 333 | 0.080 |
Why?
|
| Data Collection | 3 | 2013 | 381 | 0.080 |
Why?
|
| Copper | 2 | 2007 | 64 | 0.080 |
Why?
|
| Micronuclei, Chromosome-Defective | 2 | 2008 | 9 | 0.080 |
Why?
|
| Molecular Sequence Data | 6 | 2015 | 3892 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 1327 | 0.080 |
Why?
|
| 3' Untranslated Regions | 3 | 2005 | 163 | 0.080 |
Why?
|
| Health Education | 1 | 1992 | 222 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1996 | 782 | 0.080 |
Why?
|
| Electric Power Supplies | 1 | 1989 | 15 | 0.080 |
Why?
|
| Metagenome | 1 | 2011 | 149 | 0.080 |
Why?
|
| Retrospective Studies | 9 | 2014 | 16284 | 0.080 |
Why?
|
| Vitamin B Complex | 2 | 2013 | 41 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 74 | 0.080 |
Why?
|
| Gene Amplification | 2 | 2007 | 230 | 0.080 |
Why?
|
| Human Genome Project | 1 | 2009 | 55 | 0.080 |
Why?
|
| SEER Program | 2 | 2001 | 200 | 0.080 |
Why?
|
| RNA, Messenger | 8 | 2010 | 2821 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 1707 | 0.080 |
Why?
|
| Zinc | 2 | 2007 | 134 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2006 | 20 | 0.080 |
Why?
|
| Esophagitis | 2 | 2010 | 40 | 0.080 |
Why?
|
| Estrogens | 1 | 2012 | 504 | 0.080 |
Why?
|
| Patient Selection | 2 | 2007 | 698 | 0.080 |
Why?
|
| Disease | 1 | 2010 | 129 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2008 | 418 | 0.080 |
Why?
|
| Occupations | 2 | 1987 | 22 | 0.080 |
Why?
|
| Isoenzymes | 2 | 2003 | 231 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 263 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 218 | 0.080 |
Why?
|
| Estrogens, Non-Steroidal | 2 | 1999 | 18 | 0.080 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 11 | 0.080 |
Why?
|
| DNA Replication | 1 | 2011 | 352 | 0.080 |
Why?
|
| Evolution, Molecular | 3 | 2014 | 668 | 0.080 |
Why?
|
| Tocopherols | 1 | 2008 | 8 | 0.080 |
Why?
|
| Genes, Reporter | 4 | 2011 | 380 | 0.080 |
Why?
|
| Consumer Health Information | 1 | 2009 | 25 | 0.080 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2006 | 25 | 0.080 |
Why?
|
| Image Cytometry | 1 | 2008 | 14 | 0.080 |
Why?
|
| Drug Utilization | 1 | 2009 | 161 | 0.080 |
Why?
|
| Emigration and Immigration | 2 | 2007 | 80 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 64 | 0.080 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2008 | 18 | 0.080 |
Why?
|
| Cytodiagnosis | 1 | 2008 | 19 | 0.070 |
Why?
|
| Boron | 1 | 2008 | 3 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 459 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 683 | 0.070 |
Why?
|
| Primary Health Care | 2 | 1992 | 769 | 0.070 |
Why?
|
| Chromosome Deletion | 2 | 2008 | 647 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2001 | 62 | 0.070 |
Why?
|
| DNA Repair Enzymes | 3 | 2003 | 39 | 0.070 |
Why?
|
| Cell Survival | 2 | 2008 | 812 | 0.070 |
Why?
|
| Antigens, Nuclear | 1 | 2008 | 60 | 0.070 |
Why?
|
| Intrauterine Devices | 1 | 1988 | 14 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2009 | 90 | 0.070 |
Why?
|
| Biomarkers | 7 | 2005 | 3080 | 0.070 |
Why?
|
| Magnesium | 1 | 2008 | 123 | 0.070 |
Why?
|
| Urinary Bladder | 2 | 2006 | 243 | 0.070 |
Why?
|
| Dysgerminoma | 2 | 1987 | 5 | 0.070 |
Why?
|
| Pedigree | 2 | 2015 | 1604 | 0.070 |
Why?
|
| Maternal Exposure | 1 | 2009 | 148 | 0.070 |
Why?
|
| Random Allocation | 2 | 2004 | 441 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 2 | 2009 | 325 | 0.070 |
Why?
|
| Retinoids | 3 | 1997 | 34 | 0.070 |
Why?
|
| Amino Acid Substitution | 2 | 2011 | 398 | 0.070 |
Why?
|
| Colonic Neoplasms | 2 | 1992 | 248 | 0.070 |
Why?
|
| Sputum | 1 | 2008 | 105 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2007 | 12 | 0.070 |
Why?
|
| ADP Ribose Transferases | 1 | 2007 | 19 | 0.070 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2008 | 83 | 0.070 |
Why?
|
| Pelvis | 1 | 1988 | 71 | 0.070 |
Why?
|
| Alkylation | 1 | 2007 | 11 | 0.070 |
Why?
|
| Introns | 2 | 2006 | 300 | 0.070 |
Why?
|
| Sulfuric Acid Esters | 1 | 2007 | 9 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 211 | 0.070 |
Why?
|
| Rad51 Recombinase | 1 | 2006 | 29 | 0.070 |
Why?
|
| Genes, p16 | 2 | 2006 | 13 | 0.070 |
Why?
|
| Pneumonia | 2 | 2013 | 323 | 0.070 |
Why?
|
| Cytosol | 1 | 2007 | 161 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 697 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 33 | 0.070 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2008 | 572 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 832 | 0.070 |
Why?
|
| Luciferases | 2 | 2005 | 132 | 0.070 |
Why?
|
| G2 Phase | 2 | 2007 | 44 | 0.070 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 5 | 2007 | 21 | 0.070 |
Why?
|
| Biological Assay | 1 | 2007 | 104 | 0.070 |
Why?
|
| Telomere-Binding Proteins | 1 | 2006 | 43 | 0.060 |
Why?
|
| Twins | 1 | 2006 | 69 | 0.060 |
Why?
|
| Sex Ratio | 1 | 1986 | 12 | 0.060 |
Why?
|
| Fruit | 3 | 2011 | 220 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 39 | 0.060 |
Why?
|
| Comorbidity | 4 | 2012 | 1532 | 0.060 |
Why?
|
| Genomics | 2 | 2011 | 1501 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2000 | 314 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 3 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2006 | 372 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 80 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 242 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1462 | 0.060 |
Why?
|
| Cell Division | 1 | 2007 | 783 | 0.060 |
Why?
|
| Transients and Migrants | 2 | 2005 | 24 | 0.060 |
Why?
|
| Aminobiphenyl Compounds | 1 | 2005 | 1 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2007 | 281 | 0.060 |
Why?
|
| Premenopause | 2 | 2002 | 30 | 0.060 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2005 | 22 | 0.060 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 1988 | 163 | 0.060 |
Why?
|
| Hodgkin Disease | 3 | 1998 | 294 | 0.060 |
Why?
|
| Vegetables | 3 | 2011 | 262 | 0.060 |
Why?
|
| China | 4 | 2000 | 245 | 0.060 |
Why?
|
| Cadherins | 1 | 2006 | 171 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2012 | 259 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2009 | 553 | 0.060 |
Why?
|
| Enzyme Induction | 2 | 2007 | 104 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2007 | 352 | 0.060 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 713 | 0.060 |
Why?
|
| Diet Surveys | 1 | 2005 | 98 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 581 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 41 | 0.060 |
Why?
|
| Medical History Taking | 3 | 2006 | 108 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2002 | 70 | 0.060 |
Why?
|
| Radioimmunoassay | 2 | 2005 | 108 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 1985 | 58 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2013 | 759 | 0.060 |
Why?
|
| Blotting, Southern | 2 | 2003 | 215 | 0.060 |
Why?
|
| Bronchitis | 1 | 2005 | 34 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 203 | 0.060 |
Why?
|
| Stomach Neoplasms | 2 | 2001 | 546 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2004 | 8 | 0.060 |
Why?
|
| Genes | 1 | 2006 | 447 | 0.060 |
Why?
|
| Food | 1 | 2005 | 125 | 0.060 |
Why?
|
| Energy Intake | 3 | 2011 | 493 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 149 | 0.060 |
Why?
|
| Receptors, Calcitriol | 1 | 2005 | 69 | 0.060 |
Why?
|
| Vitamin A | 2 | 2002 | 58 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 1239 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 183 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2011 | 3348 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2005 | 139 | 0.060 |
Why?
|
| Mothers | 1 | 2007 | 354 | 0.060 |
Why?
|
| Internship and Residency | 1 | 1995 | 1176 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2003 | 797 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 1758 | 0.060 |
Why?
|
| Vitamin E | 3 | 2001 | 69 | 0.050 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 80 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2004 | 139 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2010 | 838 | 0.050 |
Why?
|
| Menopause | 1 | 2004 | 77 | 0.050 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2003 | 3 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 255 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 794 | 0.050 |
Why?
|
| Psychology | 2 | 2015 | 58 | 0.050 |
Why?
|
| Pharmacists | 1 | 2004 | 84 | 0.050 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2003 | 58 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 1094 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 70 | 0.050 |
Why?
|
| Education, Pharmacy | 1 | 2004 | 55 | 0.050 |
Why?
|
| Papillomaviridae | 2 | 1994 | 144 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2004 | 344 | 0.050 |
Why?
|
| Mouthwashes | 2 | 1994 | 10 | 0.050 |
Why?
|
| Skin | 1 | 2005 | 518 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2005 | 459 | 0.050 |
Why?
|
| Chromosome Disorders | 3 | 1996 | 311 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2003 | 101 | 0.050 |
Why?
|
| DNA Ligases | 1 | 2002 | 17 | 0.050 |
Why?
|
| Body Weight | 2 | 2011 | 989 | 0.050 |
Why?
|
| Arylsulfotransferase | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genetic Techniques | 1 | 2002 | 106 | 0.050 |
Why?
|
| Counseling | 1 | 2004 | 218 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2006 | 340 | 0.050 |
Why?
|
| Tea | 1 | 2002 | 15 | 0.050 |
Why?
|
| Marriage | 5 | 1989 | 28 | 0.050 |
Why?
|
| Sulfotransferases | 1 | 2002 | 27 | 0.050 |
Why?
|
| Diet Records | 2 | 1999 | 74 | 0.050 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2001 | 11 | 0.050 |
Why?
|
| Agriculture | 1 | 2001 | 29 | 0.050 |
Why?
|
| Genetic Testing | 3 | 2008 | 1002 | 0.050 |
Why?
|
| Medical Informatics | 1 | 2003 | 108 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2002 | 1636 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2004 | 295 | 0.050 |
Why?
|
| Computational Biology | 3 | 2014 | 810 | 0.050 |
Why?
|
| Poly T | 1 | 2001 | 3 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2001 | 56 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 160 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2004 | 414 | 0.050 |
Why?
|
| Insecticides | 1 | 2001 | 52 | 0.050 |
Why?
|
| Blood Preservation | 1 | 2001 | 29 | 0.050 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2001 | 18 | 0.050 |
Why?
|
| Poly A | 1 | 2001 | 59 | 0.050 |
Why?
|
| Urban Population | 2 | 2005 | 226 | 0.050 |
Why?
|
| Catechin | 1 | 2001 | 13 | 0.050 |
Why?
|
| Nutrition Assessment | 2 | 1999 | 136 | 0.040 |
Why?
|
| Canada | 2 | 2013 | 287 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 133 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2011 | 74 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2002 | 121 | 0.040 |
Why?
|
| Benzopyrenes | 1 | 2000 | 4 | 0.040 |
Why?
|
| Linear Models | 2 | 2012 | 680 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2013 | 182 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 1985 | 505 | 0.040 |
Why?
|
| United Kingdom | 2 | 2011 | 190 | 0.040 |
Why?
|
| Lung | 2 | 2022 | 1497 | 0.040 |
Why?
|
| Deoxyguanosine | 1 | 2000 | 13 | 0.040 |
Why?
|
| Point Mutation | 4 | 2003 | 347 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2001 | 332 | 0.040 |
Why?
|
| Marijuana Smoking | 1 | 1999 | 31 | 0.040 |
Why?
|
| Models, Genetic | 3 | 2010 | 760 | 0.040 |
Why?
|
| Quality Control | 2 | 2010 | 121 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1996 | 73 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2012 | 651 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 553 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 1999 | 50 | 0.040 |
Why?
|
| Marijuana Abuse | 1 | 1999 | 49 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 558 | 0.040 |
Why?
|
| Software Design | 1 | 1999 | 24 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2004 | 1290 | 0.040 |
Why?
|
| Testosterone | 2 | 2001 | 533 | 0.040 |
Why?
|
| Carcinogenicity Tests | 1 | 1998 | 20 | 0.040 |
Why?
|
| Genes, bcl-1 | 1 | 1998 | 5 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 1998 | 19 | 0.040 |
Why?
|
| Transfection | 1 | 2000 | 1069 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 1988 | 31 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2003 | 815 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 429 | 0.040 |
Why?
|
| Interphase | 1 | 1998 | 46 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 1998 | 79 | 0.040 |
Why?
|
| Genes, ras | 1 | 1998 | 100 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 573 | 0.040 |
Why?
|
| Chloride-Bicarbonate Antiporters | 1 | 1998 | 8 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 725 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1998 | 69 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2012 | 132 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 546 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2008 | 96 | 0.040 |
Why?
|
| Teratogens | 1 | 1998 | 88 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2010 | 700 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 144 | 0.040 |
Why?
|
| Quinone Reductases | 1 | 1997 | 3 | 0.030 |
Why?
|
| Telomere Homeostasis | 1 | 2017 | 42 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2015 | 875 | 0.030 |
Why?
|
| Reference Standards | 2 | 2011 | 236 | 0.030 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1996 | 79 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2007 | 65 | 0.030 |
Why?
|
| Treatment Failure | 1 | 1998 | 338 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 1997 | 74 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2016 | 44 | 0.030 |
Why?
|
| Animals | 5 | 2005 | 34248 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 122 | 0.030 |
Why?
|
| Y Chromosome | 1 | 1996 | 47 | 0.030 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 2 | 2006 | 6 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2905 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2016 | 12 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2007 | 13972 | 0.030 |
Why?
|
| Forestry | 1 | 1995 | 2 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2016 | 388 | 0.030 |
Why?
|
| Israel | 1 | 2015 | 45 | 0.030 |
Why?
|
| Jews | 1 | 2015 | 32 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1997 | 684 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 269 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 281 | 0.030 |
Why?
|
| Genetic Linkage | 2 | 2008 | 453 | 0.030 |
Why?
|
| X Chromosome | 1 | 1996 | 338 | 0.030 |
Why?
|
| Korea | 2 | 2010 | 35 | 0.030 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1995 | 71 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 507 | 0.030 |
Why?
|
| Object Attachment | 1 | 2015 | 49 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1995 | 118 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 107 | 0.030 |
Why?
|
| Vasectomy | 1 | 1994 | 15 | 0.030 |
Why?
|
| Coal | 1 | 1994 | 1 | 0.030 |
Why?
|
| Mining | 1 | 1994 | 8 | 0.030 |
Why?
|
| Chromosome Painting | 2 | 2004 | 16 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 109 | 0.030 |
Why?
|
| North America | 1 | 2014 | 240 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2008 | 1898 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1994 | 104 | 0.030 |
Why?
|
| Urogenital Neoplasms | 1 | 1993 | 13 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1994 | 74 | 0.030 |
Why?
|
| Infant | 5 | 1996 | 12455 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2013 | 835 | 0.030 |
Why?
|
| Activation, Metabolic | 1 | 2013 | 5 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 32 | 0.030 |
Why?
|
| Antimutagenic Agents | 1 | 1993 | 1 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 1993 | 45 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3069 | 0.030 |
Why?
|
| Betaine | 1 | 2013 | 22 | 0.030 |
Why?
|
| Internationality | 1 | 2013 | 132 | 0.030 |
Why?
|
| Smoke-Free Policy | 1 | 2012 | 3 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2012 | 26 | 0.030 |
Why?
|
| Choline | 1 | 2013 | 54 | 0.030 |
Why?
|
| Causality | 1 | 2012 | 83 | 0.030 |
Why?
|
| Financing, Government | 1 | 2012 | 30 | 0.030 |
Why?
|
| Air | 1 | 2012 | 25 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1694 | 0.020 |
Why?
|
| Physical Examination | 1 | 1993 | 158 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 89 | 0.020 |
Why?
|
| Adolescent Development | 1 | 2012 | 25 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2012 | 37 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2012 | 63 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 399 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2002 | 169 | 0.020 |
Why?
|
| raf Kinases | 1 | 2011 | 7 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 78 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1994 | 170 | 0.020 |
Why?
|
| Educational Measurement | 1 | 1995 | 323 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 368 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2011 | 6 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 266 | 0.020 |
Why?
|
| Food, Organic | 1 | 2011 | 3 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2012 | 84 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 196 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1993 | 480 | 0.020 |
Why?
|
| Single Parent | 1 | 2011 | 1 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 40 | 0.020 |
Why?
|
| Gene Expression | 3 | 2002 | 1561 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 28 | 0.020 |
Why?
|
| Specialization | 1 | 1992 | 75 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 2 | 2002 | 29 | 0.020 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2011 | 19 | 0.020 |
Why?
|
| Siblings | 1 | 2012 | 197 | 0.020 |
Why?
|
| Mammography | 1 | 1992 | 114 | 0.020 |
Why?
|
| Ki-1 Antigen | 1 | 2011 | 28 | 0.020 |
Why?
|
| Hair Dyes | 1 | 1990 | 2 | 0.020 |
Why?
|
| Meiosis | 1 | 1991 | 112 | 0.020 |
Why?
|
| Television | 1 | 2011 | 71 | 0.020 |
Why?
|
| Sports | 1 | 2011 | 62 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1991 | 229 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 158 | 0.020 |
Why?
|
| Gonorrhea | 1 | 1991 | 38 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1996 | 538 | 0.020 |
Why?
|
| Pesticides | 1 | 2010 | 22 | 0.020 |
Why?
|
| Singapore | 1 | 2010 | 16 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 31 | 0.020 |
Why?
|
| Medicine | 1 | 1992 | 97 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1120 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2011 | 295 | 0.020 |
Why?
|
| Twin Studies as Topic | 1 | 2010 | 15 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 517 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 230 | 0.020 |
Why?
|
| Karyopherins | 1 | 2010 | 36 | 0.020 |
Why?
|
| Sexual Partners | 1 | 1991 | 87 | 0.020 |
Why?
|
| Guanine | 1 | 2010 | 61 | 0.020 |
Why?
|
| Contraception | 1 | 1991 | 57 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 357 | 0.020 |
Why?
|
| Massachusetts | 1 | 2010 | 125 | 0.020 |
Why?
|
| Tars | 1 | 1990 | 1 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 76 | 0.020 |
Why?
|
| Radiation, Nonionizing | 1 | 1989 | 1 | 0.020 |
Why?
|
| Income | 1 | 1991 | 134 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 133 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 112 | 0.020 |
Why?
|
| Equipment Safety | 1 | 1989 | 36 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2001 | 53 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 361 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 187 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1990 | 135 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2001 | 221 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 156 | 0.020 |
Why?
|
| Actins | 2 | 2003 | 345 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 125 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 142 | 0.020 |
Why?
|
| Curriculum | 1 | 1995 | 725 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2011 | 186 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 806 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 2 | 2001 | 8 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1103 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1756 | 0.020 |
Why?
|
| Plant Preparations | 2 | 1999 | 18 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2010 | 209 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 2008 | 34 | 0.020 |
Why?
|
| beta-Tocopherol | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2011 | 680 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2008 | 4 | 0.020 |
Why?
|
| Software Validation | 1 | 1988 | 11 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 38 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2008 | 21 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 376 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1988 | 77 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1992 | 474 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 24 | 0.020 |
Why?
|
| Overweight | 1 | 2011 | 364 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2009 | 79 | 0.020 |
Why?
|
| Homosexuality | 1 | 1988 | 18 | 0.020 |
Why?
|
| Bronchi | 1 | 2008 | 97 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Tissue Adhesions | 1 | 1988 | 30 | 0.020 |
Why?
|
| Cognition | 1 | 2013 | 731 | 0.020 |
Why?
|
| Nitrites | 1 | 1988 | 49 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 114 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 2007 | 42 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2008 | 158 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 265 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2007 | 24 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 202 | 0.020 |
Why?
|
| Motivation | 1 | 1990 | 319 | 0.020 |
Why?
|
| S Phase | 1 | 2007 | 73 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 101 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 255 | 0.020 |
Why?
|
| Valine | 1 | 2007 | 115 | 0.020 |
Why?
|
| Radiation Effects | 1 | 2006 | 14 | 0.020 |
Why?
|
| Twins, Monozygotic | 1 | 2007 | 117 | 0.020 |
Why?
|
| Guanosine | 1 | 2006 | 11 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Thymidine | 1 | 2006 | 54 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2006 | 32 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2007 | 185 | 0.020 |
Why?
|
| Cryptorchidism | 1 | 1986 | 37 | 0.020 |
Why?
|
| Social Support | 1 | 2009 | 344 | 0.020 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2006 | 16 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 1 | 1988 | 119 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 80 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2006 | 39 | 0.020 |
Why?
|
| Sunburn | 1 | 2005 | 4 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 2523 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1016 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2006 | 152 | 0.020 |
Why?
|
| RNA Interference | 1 | 2007 | 503 | 0.020 |
Why?
|
| Karyotyping | 2 | 1996 | 323 | 0.020 |
Why?
|
| Recurrence | 1 | 2009 | 1418 | 0.020 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2005 | 4 | 0.020 |
Why?
|
| Teratoma | 1 | 1986 | 120 | 0.020 |
Why?
|
| Electromagnetic Fields | 1 | 1985 | 27 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 1996 | 8191 | 0.020 |
Why?
|
| Electronics | 1 | 1985 | 43 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2005 | 189 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 81 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2005 | 100 | 0.020 |
Why?
|
| Cryptoxanthins | 1 | 2005 | 2 | 0.010 |
Why?
|
| Xanthophylls | 1 | 2005 | 4 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2005 | 29 | 0.010 |
Why?
|
| Zeaxanthins | 1 | 2005 | 9 | 0.010 |
Why?
|
| Iron | 1 | 2007 | 270 | 0.010 |
Why?
|
| Lutein | 1 | 2005 | 15 | 0.010 |
Why?
|
| Isomerism | 1 | 2005 | 31 | 0.010 |
Why?
|
| Food Analysis | 1 | 2005 | 26 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2005 | 140 | 0.010 |
Why?
|
| Calcitriol | 1 | 2005 | 80 | 0.010 |
Why?
|
| Palliative Care | 1 | 2008 | 429 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 79 | 0.010 |
Why?
|
| Chromosome Segregation | 1 | 2004 | 63 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1988 | 450 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 369 | 0.010 |
Why?
|
| Infertility, Male | 1 | 1987 | 263 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 634 | 0.010 |
Why?
|
| Weight Gain | 1 | 2007 | 400 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 60 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 219 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2004 | 59 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 345 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 113 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 376 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 1303 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2003 | 27 | 0.010 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2003 | 19 | 0.010 |
Why?
|
| Oropharynx | 1 | 2003 | 34 | 0.010 |
Why?
|
| Professional-Patient Relations | 1 | 2004 | 84 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 90 | 0.010 |
Why?
|
| DNA-Formamidopyrimidine Glycosylase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Papanicolaou Test | 1 | 2003 | 33 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 11 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2003 | 14 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2003 | 48 | 0.010 |
Why?
|
| Sunlight | 1 | 2003 | 24 | 0.010 |
Why?
|
| Chloramphenicol | 1 | 2002 | 28 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 1101 | 0.010 |
Why?
|
| DNA Ligase ATP | 1 | 2002 | 11 | 0.010 |
Why?
|
| Hand Disinfection | 1 | 2001 | 16 | 0.010 |
Why?
|
| Hygiene | 1 | 2001 | 27 | 0.010 |
Why?
|
| Cardia | 1 | 2001 | 27 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2001 | 21 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2001 | 39 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 67 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2001 | 49 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2001 | 88 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 118 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 2001 | 48 | 0.010 |
Why?
|
| Cryopreservation | 1 | 2001 | 73 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2000 | 50 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2001 | 154 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2001 | 236 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 777 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2000 | 48 | 0.010 |
Why?
|
| Demography | 1 | 2000 | 239 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2000 | 65 | 0.010 |
Why?
|
| Stigmasterol | 1 | 1999 | 3 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2000 | 122 | 0.010 |
Why?
|
| Genistein | 1 | 1999 | 39 | 0.010 |
Why?
|
| Alcoholism | 1 | 2001 | 231 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 662 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2000 | 663 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2001 | 799 | 0.010 |
Why?
|
| Metaphase | 1 | 1996 | 45 | 0.010 |
Why?
|
| Ataxia Telangiectasia | 1 | 1996 | 15 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 538 | 0.010 |
Why?
|
| Base Composition | 1 | 1995 | 71 | 0.010 |
Why?
|
| Environmental Pollutants | 1 | 1996 | 68 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1988 | 235 | 0.010 |
Why?
|
| New England | 1 | 1995 | 12 | 0.010 |
Why?
|
| Bias | 1 | 1996 | 131 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1996 | 257 | 0.010 |
Why?
|
| Smoke | 1 | 1995 | 61 | 0.010 |
Why?
|
| Observer Variation | 1 | 1996 | 298 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1996 | 324 | 0.010 |
Why?
|
| Prostatic Diseases | 1 | 1994 | 15 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1994 | 2 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1993 | 52 | 0.010 |
Why?
|
| Genome | 1 | 1995 | 472 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1993 | 185 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 1993 | 72 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1993 | 395 | 0.010 |
Why?
|
| Parity | 1 | 1992 | 78 | 0.010 |
Why?
|
| Epithelium | 1 | 1993 | 362 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 417 | 0.010 |
Why?
|
| Cause of Death | 1 | 1994 | 474 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 2000 | 1263 | 0.010 |
Why?
|
| Nitroso Compounds | 1 | 1988 | 8 | 0.000 |
Why?
|
| Aphrodisiacs | 1 | 1988 | 5 | 0.000 |
Why?
|
| Death Certificates | 1 | 1987 | 9 | 0.000 |
Why?
|
| Hydrocarbons | 1 | 1987 | 8 | 0.000 |
Why?
|
| Single Person | 1 | 1987 | 2 | 0.000 |
Why?
|
| Divorce | 1 | 1987 | 6 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1988 | 77 | 0.000 |
Why?
|
| Administration, Inhalation | 1 | 1988 | 180 | 0.000 |
Why?
|
| Acute Disease | 1 | 1989 | 1108 | 0.000 |
Why?
|